// App-Quantinova.ai

: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Researchers

Presenter

  • Won-Seog Kim

Principal Investigators

  • Seok-Goo Cho

  • Isidro Jarque

  • Elzbieta Iskierka-Jazdzewska

  • Michelle Limei Poon

  • H. Miles Prince

  • Sung Yong Oh

  • Francesca Lim

  • Cecilia Carpio

  • Tran-Der Tan

  • Sabarish Ayyappan

  • Antonio Gutierrez

  • Jingjin Li

  • Melanie Ufkin

  • Min Zhu

  • Aafia Chaudhry

  • Hesham Mohamed

  • Srikanth R. Ambati

  • Jan Walewski

Medical Centers

  • Hospital Universitari Son Espases, Palma, Spain

  • Singapore General Hospital, Singapore, Singapore

  • Dong-A University Hospital, Busan, Korea, Republic of (South)

  • Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie Państwowy Instytut Badawczy, Warszawa, Poland

  • Epworth Healthcare and University of Melbourne, East Melbourne, Australia

  • Samsung Medical Center, Center for Hematologic Malignancy, Seoul, Korea, Republic of (South)

  • Seoul National University Hospital, Seoul, Korea, Republic of (South)

  • Hematology and Medical Oncology Koo Foundation Sun Yat Sen Cancer Center, Taipei City, Taiwan

  • Hematology Oncology National University Hospital, Singapore, Singapore

  • University of Iowa Hospital and Clinics, Iowa City, IA

  • The Catholic University of Korea, Seoul St. Mary's Hospital Hematology, Seoul, Korea, Republic of (South)

  • H Copernicus Memorial Hospital, Department of Hematology, Medical University of Łódź, Łódź, Poland

  • Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron, Autonomous University of Barcelona (UAB), Barcelona, Spain

  • Hospital Universitari I Politecnic La Fe, Valencia, Spain

Locations

  • Spain

  • Turkmenistan

  • Taiwan

  • Australia

  • Singapore

  • Poland

  • Republic of South Korea

  • United States

Companies

  • Regeneron Pharmaceut

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

Biomarkers

  • Twist-related protein 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multicenteric

  • Global

  • pivotal

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved